Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review

Oncotarget
Jung Han KimBum Jun Kim

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option in the fight against advanced non-small-cell lung cancer (NSCLC). KRAS is the most frequently mutated oncogene in NSCLC. We performed this meta-analysis to investigate if KRAS mutation status affects survival benefits of ICIs in patients with advanced NSCLC. Electronic databases were searched for eligible studies. We included randomized trials with the data of overall survival stratified by KRAS mutation status. From 3 eligible studies, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type tumor were included in the meta-analysis. Compared to chemotherapy with docetaxel, ICIs improved overall survival in patients with previously treated KRAS mutant NSCLC (hazard ratio = 0.64 [95% confidence interval, 0.43-0.96], P = 0.03). For patients with KRAS wild-type NSCLC, however, ICIs did not prolong overall survival over that with chemotherapy (hazard ratio = 0.88 [95% confidence interval, 0.68-1.13], P = 0.30). In conclusion, ICIs as a salvage therapy improved overall survival over that with docetaxel in advanced NSCLC patients with KRAS mutation, but not in those with KRAS wild-type tumor. These results suggest that KRAS mutation status may be ...Continue Reading

Associated Clinical Trials

References

Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Mar 8, 2014·Oncoimmunology·Stéphane ChampiatJean Charles Soria
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Mar 19, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Chang-Mo OhUNKNOWN Community of Population-Based Regional Cancer Registries
Oct 4, 2016·Journal of the Chinese Medical Association : JCMA·Yuh-Min Chen
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 22, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chee Khoon LeeJames Chih-Hsin Yang
Jan 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhong-Yi DongYi-Long Wu

❮ Previous
Next ❯

Citations

Aug 1, 2018·Cancers·Yosuke Miura, Noriaki Sunaga
Jan 29, 2020·Virchows Archiv : an International Journal of Pathology·Eleni A KaratrasoglouAngelica A Saetta
Oct 16, 2019·Frontiers in Oncology·Haitang YangRen-Wang Peng
Nov 27, 2020·Biochemical Society Transactions·Atanu Chakraborty
Jul 26, 2019·Biochemical Society Transactions·Simone LanfrediniEric O'Neill
Feb 18, 2020·Cancer Treatment Reviews·Alex FriedlaenderAlfredo Addeo
Apr 4, 2021·International Journal of Molecular Sciences·Sara Elena RebuzziCarlo Genova
Apr 3, 2021·Cancer Treatment Reviews·Alfredo AddeoAlex Friedlaender
Apr 20, 2021·Frontiers in Oncology·Alex FriedlaenderAlfredo Addeo
May 3, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Patrizia FroeschUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Jun 26, 2021·Nature Reviews. Clinical Oncology·Michael J GrantSarah B Goldberg
Aug 22, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Colin R LindsayJulien Mazières
Aug 28, 2021·Cancers·Ana Nacarino-PalmaPedro M Fernández-Salguero
Apr 9, 2020·Oncology Research and Treatment·Diego Kauffmann-GuerreroHeiko Golpon

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.